Drugs Made In America Acquisition DMAA Institutional Ownership

Ownership Summary

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is held by 39 institutional investors per 13F filings through March 2026.

• They owned 115.2% of outstanding stock in March 2026, up from 112.1% the prior quarter.
• Their total shares held in DMAA increased 15.11% from the prior quarter, while the number of investors in Drugs Made In America Acquisition increased 56.0% year over year.
• Of these 39 holders, 13 added to their stakes in Drugs Made In America Acquisition, 9 trimmed positions, and 17 made no changes.
• In total, institutional investors held 24.19Mn shares in Drugs Made In America Acquisition as of March 2026, up by 3.18Mn shares quarter on quarter, and up 2.2Mn shares year over year.
• As of March 31, 2026, Karpus Management, Inc. held the largest stake in Drugs Made In America Acquisition with 2.53Mn shares, accounting for 12.05% of total shares outstanding.
• The biggest buyers of Drugs Made In America Acquisition for the quarter ending March 2026 included Jpmorgan Chase & Co (1.32Mn), HIGHBRIDGE CAPITAL MANAGEMENT LLC (1.32Mn), MIZUHO SECURITIES USA LLC (566.52K), METEORA CAPITAL, LLC (380.3K), Shaolin Capital Management LLC (347.93K).
• Top sellers of DMAA stock for the quarter ending March 2026 included Hudson Bay Capital Management LP (1.25Mn), GLAZER CAPITAL, LLC (138.02K), Goldman Sachs Group Inc (119.69K), Lineage Point Capital LP (31.84K), AQR Arbitrage LLC (13.63K).
• Business Quant data shows the 10 biggest positions in Drugs Made In America Acquisition as of March 2026 are held by Karpus Management, Inc. (2.53Mn), First Trust Capital Management L.P. (2.24Mn), MIZUHO SECURITIES USA LLC (2.0Mn), GLAZER CAPITAL, LLC (1.68Mn), Westchester Capital Management, LLC (1.67Mn), Polar Asset Management Partners Inc. (1.6Mn), WOLVERINE ASSET MANAGEMENT LLC (1.55Mn), Jpmorgan Chase & Co (1.37Mn), HIGHBRIDGE CAPITAL MANAGEMENT LLC (1.32Mn), ARISTEIA CAPITAL, L.L.C. (881.72K).